Other Transaction Agreement HR00112090118
Award Date 9/30/20
Potential Completion Date 10/31/25
Potential Value $51M
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Not listed Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Competed
Major Defense Program
Not listed Pricing Type
Other
Place of Performance
Cambridge, MA 02139, USA
Solicitation Procedures
Broad Agency Announcement
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the Department of Health and Human Services (HHS), to Modernatx, Inc. The $81,397,873.67 cost-plus-fixed-fee contract is to advance the development of a messenger RNA (mRNA) vaccine for the prevention of Zika virus. The contract has a completion date of July 1, 2024. Modernatx, Inc. is a for-profit manufacturer of pharmaceutical goods that has provided...
- <p>The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense (DOD - Army - USASC) awarded a Definitive Contract valued at $7,837,399,999.00 to Moderna US, Inc. Moderna US Inc. Division for COVID-19 MRNA Vaccines. The place of performance will be in Cambridge, MA 02139, USA and the period of performance is from July 28, 2022 through March 31, 2023. The pricing structure is Firm Fixed Price.</p>
- This definitive contract was awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to Moderna US, Inc. for COVID-19 vaccinations in support of the 2022 Fall Vaccine Campaign. The $7.8 billion firm fixed price contract is a transfer from the original awarding agency, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, and represents continuation of vaccine production...
- This federal contract award, valued at $31,863,305.85, is for the DARPA "Living Foundries: 1000 Molecules" program, which aims to build a scalable, integrated, rapid design and prototyping infrastructure for engineering biology. The prime contractor is the Massachusetts Institute of Technology (MIT), a premier private research university. The contract has no set-aside designation and is a definitive contract with a cost-no-fee pricing type. Major subcontractors include the Broad...
- This federal contract award, W911QY2190008, was issued by the Joint PEO Chemical and Biological Defense, a subcomponent of the U.S. Department of the Army, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The $62,096,250.00 Other Transaction Agreement is for the development of a "COVID-19" Monoclonal Antibody (MAB) Sponsorship Prototype. Resilience Government Services, a technology-focused biomanufacturing company, has previously received federal...
- This federal contract award, valued at $1,908.33, was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Moderna COVID-19 vaccines for the 6-month to 11-year-old age group under Emergency Use Authorization (EUA), with an ultimate completion date of November 12, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 10 awarded a $12,302.50 firm fixed price purchase order to Modernatx, Inc. of Cambridge, Massachusetts for COVID vaccines. The contract runs from August 15, 2023 through December 31, 2023 to support VHA's mission of providing healthcare services to veterans. As the prime contractor, Modernatx will deliver COVID vaccines to aid VA medical centers and clinics located in the New England region in...
- This federal contract award, valued at $16,888.60, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 0.25mL doses of the Moderna COVID-19 vaccine for individuals aged 6 months to 11 years, under the Emergency Use Authorization (EUA). The award has an ultimate completion date of October 20, 2023. This contract is a delivery order with a firm fixed-price...
- This federal contract award, valued at $15,189.20, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 0.25 mL doses of the Moderna COVID-19 vaccine for individuals aged 6 months to 11 years under the Emergency Use Authorization (EUA). The contract has an ultimate completion date of November 27, 2023. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to...
- This is a $2,605.08 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of MODERNA COVID 24-25(6M-11Y)EUA 0.25ML vaccines. The award has an ultimate completion date of July 8, 2025 and is not set aside. Amerisourcebergen Drug Corp is the prime contractor, and this delivery order is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held with DLA Troop Support Medical to...